Lexicon Pharma (LXRX): PDUFA Date Extension A Speedbump, First Pass Approval Still Likely - Wedbush
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Lexicon Pharmaceuticals (NASDAQ: LXRX). The analyst believes the three month PDUFA date delay for telotristat etiprate in carcinoid syndrome is minor and no announcement of an advisory committee meeting is a positive signal for the approval chances of the drug. Given the robustness of the data package, the analyst continues to expect first pass approval.
No change to the price target of $33.
Shares of Lexicon Pharmaceuticals closed at $18.83 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Securities Downgrades Community Health (CYH) to Underperform
- Lexicon Pharma (LXRX) Announces Sotagliflozin Phase 2 Met Primary Endpoint in T2D
- Dougherty & Co Upgrades Entegris Inc (ENTG) to Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, FDA
Related EntitiesLiana Moussatos, PDUFA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!